×

Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times. (English) Zbl 1429.62551

Summary: Modeling clinical endpoints as a function of change in antiretroviral therapy (ART) attempts to answer one simple but very challenging question: was the change in ART beneficial or not? We conceive a similar scientific question of interest in the current manuscript except that we are interested in modeling the time of ART regimen change rather than a comparison of two or more ART regimens. The answer to this scientific riddle is unknown and has been difficult to address clinically. Naturally, ART regimen change is left to a participant and his or her provider and so the date of change depends on participant characteristics. There exists a vast literature on how to address potential confounding and those techniques are vital to the success of the method here. A more substantial challenge is devising a systematic modeling strategy to overcome the missing time of regimen change for those participants who do not switch to second-line ART within the study period even after failing the initial ART. In this article, we adopt and apply a statistical method that was originally proposed for modeling infusion trial data, where infusion length may be informatively censored, and argue that the same strategy may be employed here. Our application of this method to therapeutic HIV/AIDS studies is new and interesting. Using data from the AIDS Clinical Trials Group (ACTG) Study A5095, we model immunological endpoints as a polynomial function of a participant’s switching time to second-line ART for 182 participants who already failed the initial ART. In our analysis, we find that participants who switch early have somewhat better sustained suppression of HIV-1 RNA after virological failure than those who switch later. However, we also found that participants who switched very late, possibly censored due to the end of the study, had good HIV-1 RNA suppression, on average. We believe our scientific conclusions contribute to the relevant HIV literature and hope that the basic modeling strategy outlined here would be useful to others contemplating similar analyses with partially missing treatment length data.

MSC:

62P10 Applications of statistics to biology and medical sciences; meta analysis
62N02 Estimation in survival analysis and censored data
92C50 Medical applications (general)
PDFBibTeX XMLCite
Full Text: DOI DOI

References:

[1] Cox, Regression models and life-tables, Journal of the Royal Statistical Society, Series B 34 pp 187– (1972) · Zbl 0243.62041
[2] Deeks, Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia, AIDS 161 pp 201– (2002) · doi:10.1097/00002030-200201250-00009
[3] Deeks, Sustained CD4 T-cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodefiency virus infection, J. Infect. Dis. 181 pp 946– (2000) · doi:10.1086/315334
[4] Gulick, Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection, The New England Journal of Medicine 350 pp 1850– (2004) · doi:10.1056/NEJMoa031772
[5] Gulick, Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial, JAMA 296 pp 769– (2006) · doi:10.1001/jama.296.7.769
[6] Johnson, Treatment-competing events in dynamic regimes, Lifetime Data Analysis 14 pp 196– (2008) · Zbl 1147.62093 · doi:10.1007/s10985-007-9051-3
[7] Johnson, Estimating mean response as a function of treatment duration in an observational study, where duration may be informatively censored, Biometrics 60 pp 315– (2004) · Zbl 1110.62153 · doi:10.1111/j.0006-341X.2004.00175.x
[8] Johnson, Semiparametric inference in observational duration-response studies, with duration possibly right-censored, Biometrika 92 pp 605– (2005) · Zbl 1152.62390 · doi:10.1093/biomet/92.3.605
[9] Li, Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group study A5095, Journal of the American Statistical Association 107 pp 542– (2012) · Zbl 1328.62591 · doi:10.1080/01621459.2011.646932
[10] Lunceford, Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials, Biometrics 58 pp 48– (2002) · Zbl 1209.62307 · doi:10.1111/j.0006-341X.2002.00048.x
[11] Murphy, Marginal mean models for dynamic regimes, Journal of the American Statistical Association 96 pp 1410– (2001) · Zbl 1051.62114 · doi:10.1198/016214501753382327
[12] Napravnik, HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia, J Acquir Immune Defic Syndr 40 pp 34– (2005) · doi:10.1097/01.qai.0000174929.87015.d6
[13] Ribaudo, Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts, The Journal of Infectious Diseases 197 pp 1006– (2008) · doi:10.1086/529208
[14] Riddler, A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: Aids clinical trials group study a5115, Antiviral therapy 12 pp 531– (2007)
[15] Rubin, Estimating causal effects of treatments in randomized and nonrandomized studies, Journal of Educational Psychology 66 pp 688– (1974) · doi:10.1037/h0037350
[16] Spritzler, Two-sample tests of area-under-the-curve in the presence of missing data, The International Journal of Biostatistics 4 pp 1– (2008) · doi:10.2202/1557-4679.1068
[17] Yeh, A comparison of numerical integrating algorithms by trapezoidal, lagrange and spline approximation, Journal of Pharmacokinetics and Pharmacodynamics 6 pp 79– (1978) · doi:10.1007/BF01066064
[18] Zhang, Inference on treatment effects from a randomize clincal trial in the presence of premature treatment discontinuation: the synergy trial, Biostatistics 12 pp 258– (2011) · doi:10.1093/biostatistics/kxq054
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.